Scheduled Maintenance Notice
Please note that Researcher Profiles will be undergoing scheduled maintenance on Wednesday 7th Oct, from 8:00am to 9:00am. During this time, the Researcher Profiles system will be unavailable. We apologise for any inconvenience and appreciate your understanding.
Select Publications
Conference Papers
, 2009, 'DIETARY KRILL OIL SUPPLEMENTATION SIGNIFICANTLY REDUCES HEPATOMEGALY, HEPATIC STEATOSIS AND HYPERCHOLESTEROLEMIA IN HIGH-FAT FED MICE', in ATHEROSCLEROSIS SUPPLEMENTS, ELSEVIER IRELAND LTD, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000207957101042&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2009, 'DIETARY MILK PHOSPHOLIPID AS A CARDIOVASCULAR NUTRACEUTICAL', in ATHEROSCLEROSIS SUPPLEMENTS, ELSEVIER IRELAND LTD, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000207957101001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Conference Abstracts
, 2024, 'Abstract B007: High-risk pediatric cancer models in zebrafish, mouse and short-term culture predict individual patient responses to therapy', in Cancer Research, American Association for Cancer Research (AACR), Vol. 84, pp. b007 - b007, http://dx.doi.org/10.1158/1538-7445.pediatric24-b007
, 2024, 'Abstract 5475: Development of high-throughput 3D bioprinted pediatric models for precision medicine', in Cancer Research, American Association for Cancer Research (AACR), Vol. 84, pp. 5475 - 5475, http://dx.doi.org/10.1158/1538-7445.am2024-5475
, 2023, 'Abstract 4670: True bench-to-bedside science: An international pilot study modeling hard-to-cure pediatric cancers to prioritize therapeutic intervention', in Cancer Research, American Association for Cancer Research (AACR), Vol. 83, pp. 4670 - 4670, http://dx.doi.org/10.1158/1538-7445.am2023-4670
, 2020, 'Abstract A35: P-Glycoprotein is a resistance mechanism for conventional induction chemotherapy but not ALK inhibitors in high-risk neuroblastoma', in Cancer Research, American Association for Cancer Research (AACR), Vol. 80, pp. a35 - a35, http://dx.doi.org/10.1158/1538-7445.pedca19-a35
, 2019, 'Molecular targeted therapies and precision medicine for children with neuroblastoma and other refractory malignancies', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 23 - 24, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'P-Glycoprotein is a resistance mechanism for conventional induction chemotherapy but not ALK inhibitors in high-risk neuroblastoma', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CANADA, Montreal, Vol. 80, pp. 61 - 61, presented at AACR Special Conference on the Advances in Pediatric Cancer Research, CANADA, Montreal, 17 September 2019 - 20 September 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000551367400079&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2019, 'Abstract 2884: Establishment of patient-derived xenograft models for high-risk neuroblastoma', in Cancer Research, American Association for Cancer Research (AACR), Vol. 79, pp. 2884 - 2884, http://dx.doi.org/10.1158/1538-7445.am2019-2884
, 2019, 'Abstract 2884: Establishment of patient-derived xenograft models for high-risk neuroblastoma', American Association for Cancer Research (AACR), pp. 2884 - 2884, presented at Tumor Biology, http://dx.doi.org/10.1158/1538-7445.sabcs18-2884
, 2019, 'Abstract 4741: Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies', American Association for Cancer Research (AACR), pp. 4741 - 4741, presented at Experimental and Molecular Therapeutics, http://dx.doi.org/10.1158/1538-7445.sabcs18-4741
, 2019, 'Abstract 4741: Re-evaluating the role of P-glycoprotein in the resistance of high-risk neuroblastoma to standard-of-care chemotherapies', in Cancer Research, American Association for Cancer Research (AACR), Vol. 79, pp. 4741 - 4741, http://dx.doi.org/10.1158/1538-7445.am2019-4741
, 2019, 'Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Atlanta, GA, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Atlanta, GA, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-3111
, 2018, 'Abstract LB-138: Zero Childhood Cancer: A comprehensive precision medicine platform for children with high-risk cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 78, pp. lb-138-lb-138, http://dx.doi.org/10.1158/1538-7445.am2018-lb-138
, 2018, 'Zero childhood cancer – Accelerating translation of experimental oncology: Better matching drug to target', in Pathology, Elsevier, Vol. 50, pp. s31, http://dx.doi.org/10.1016/j.pathol.2017.12.072
Preprints
, Engineered paediatric tumours retain maintains tumour genotype and phenotype for precision medicine, http://dx.doi.org/10.1101/2024.11.17.619539
, Inclusion of JNK-independent drugs within multi-agent chemotherapy improves response in relapsed high-risk neuroblastoma, http://dx.doi.org/10.1101/2025.04.26.650760
, Preclinical trial supports dual inhibition of BCL2 and Aurora kinase A for MYCN -amplified high-risk neuroblastoma, http://dx.doi.org/10.64898/2026.09.06.749004
Other
, 2025, Data from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.c.7948327
, 2025, Figure 2 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644702
, 2025, Figure 3 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644699
, 2025, Figure 4 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644696
, 2025, Figure 5 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644693
, 2025, Figure S1 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644690
, 2025, Figure S2 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644687
, 2025, Figure S3 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644684
, 2025, Figure S4 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644681
, 2025, Table 1 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644678
, 2025, Table 2 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644675
, 2025, Table S1 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644672
, 2025, Table S2 from Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision Therapy, http://dx.doi.org/10.1158/2767-9764.29644669
, 2023, Data from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.c.6767498
, 2023, Data from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.c.6767498.v3
, 2023, Supplementary Figures and Figure Legends from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000213.v1
, 2023, Supplementary Figures and Figure Legends from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000213
, 2023, Supplementary Figures from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000210.v1
, 2023, Supplementary Figures from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000210
, 2023, Supplementary Materials and Methods from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000207.v1
, 2023, Supplementary Materials and Methods from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000207
, 2023, Supplementary Tables S1-S7 from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000204.v1
, 2023, Supplementary Tables S1-S7 from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.24000204
, 2023, Data from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.c.6767498.v2
, 2023, Supplementary Figures from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.23952251
, 2023, Supplementary Figures from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.23952251.v1
, 2023, Data from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.c.6767498.v1
, 2023, Supplementary Figures from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.23808560.v1
, 2023, Supplementary Figures from High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer, http://dx.doi.org/10.1158/0008-5472.23808560